摘要分子分型概念作为乳腺癌个体化综合治疗发展史上的一个里程碑，量化地定义了乳腺癌不再是单一疾病，而是在发病风险、自然病程、治疗反应等方面迥异的一组异质性疾病。分子分型对全身治疗的疗效预测及对全身转移和死亡风险的预后价值均已得到广泛的研究验证，但它与LRR风险的相关性，以及对放疗策略的指导作用也尚需要更多关注。本综述将就分子分型与LRR风险的相关性，以及分子分型对放疗策略的指导价值展开讨论。

abstractsAs a milestone in the development of personalized comprehensive treatment for breast cancer, molecular subtype classification quantitatively characterizes breast cancer as heterogeneous diseases rather than a single disease in terms of onset risk, natural course, and treatment response. The significance of molecular subtype classification has been widely confirmed in prediction of the efficacy of systemic treatment and prognosis of systemic metastases and risk of death. However, the association between molecular subtype and local?regional recurrence ( LRR) risk as well as the impact of molecular subtype classification on radiotherapy strategy still needs more attention. This review discusses the association between molecular subtype and LRR risk as well as the significance of molecular subtype classification in guiding radiotherapy strategy.